Nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
During World War II the Germans experimented with the idea of the schnorchel (snorkel) from captured Dutch submarines but did not see the need for them until rather late in the war. The schnorchel is a retractable pipe that supplies air to the diesel engines while submerged at periscope depth, allowing the boat to cruise and recharge its batteries while maintaining a degree of stealth. Especially as first implemented however, it turned out to be far from a perfect solution. There were problems with the device's valve sticking shut or closing as it dunked in rough weather. Since the system used the entire pressure hull as a buffer, the diesels would instantaneously suck huge volumes of air from the boat's compartments, and the crew often suffered painful ear injuries. Speed was limited to 8 knots (15 km/h), lest the device snap from stress. The schnorchel also created noise that made the boat easier to detect with sonar, yet more difficult for the on-board sonar to detect signals from other vessels. Finally, allied radar eventually became sufficiently advanced that the schnorchel mast could be detected beyond visual range. In clear weather, diesel exhausts can be seen on the surface to a distance of about three miles, while "periscope feather" (the wave created by the snorkel or periscope moving through the water) is visible from far off in calm sea conditions. Modern radar is also capable of detecting a snorkel in calm sea conditions.
=== Xen and final release (2015–2020) === The release of the Xen part of the game had been the most difficult, since the team wanted to redesign the levels to overcome the poor perception that they had in Half-Life's original release. The team said, "We want our version of Xen to feel like it really belongs with the rest of the game in terms of mechanics, cohesion and progression," while at the same time, they wanted "to push the boundaries and explore this unique and varied setting; to build an experience that feels both fresh and familiar to players from all walks of Half-Life veterancy." Developing their new version of Xen was a chicken-or-the-egg dilemma, as without level design it was difficult to develop art assets, and without art assets it was hard to come up with cohesive level designs. They also wanted to give more story elements there, such as why human scientists were studying the world of Xen in the first place, trying to capture the same type of world-building by level design that Valve had been able to with the first parts of Half-Life. They also significantly reworked the boss battles to be more challenging and representative of the area they had in mind. Ultimately, the team expanded out Xen from about a one-hour experience in the original Half-Life to four hours in Black Mesa.
Caffeine has been found to increase striatal dopamine in animal models, as well as inhibit the inhibitory effect of adenosine receptors on dopamine receptors, however the implications for humans are unknown. Unlike most stimulants, caffeine has no addictive potential. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, per a study on drug abuse liability published in a NIDA research monograph that described a group preferring placebo over caffeine. In large telephone surveys only 11% reported dependence symptoms. However, when people were tested in labs, only half of those who claim dependence actually experienced it, casting doubt on caffeine's ability to produce dependence and putting societal pressures in the spotlight. Coffee consumption is associated with a lower overall risk of cancer. This is primarily due to a decrease in the risks of hepatocellular and endometrial cancer, but it may also have a modest effect on colorectal cancer. There does not appear to be a significant protective effect against other types of cancers, and heavy coffee consumption may increase the risk of bladder cancer. A protective effect of caffeine against Alzheimer's disease is possible, but the evidence is inconclusive. Moderate coffee consumption may decrease the risk of cardiovascular disease, and it may somewhat reduce the risk of type 2 diabetes. Drinking 1–3 cups of coffee per day does not affect the risk of hypertension compared to drinking little or no coffee.
Martin Bright (born 5 June 1966); worked for the BBC World Service and The Guardian; political editor of New Statesman, The Spectator, The Jewish Chronicle's political editor and worked at Tony Blair Faith Foundation; has closely monitored rise of Muslim extremism, terrorist attacks in Britain and abroad, and aspects of British governmental relations with Muslim community in the United Kingdom; founded New Deal of the Mind, a charitable company to promote employment in creative fields and working with organisations, government and all political parties. In 2001, wrote "The Great Koran Con Trick" in the New Statesman and in Channel Four documentary, Who Speaks for Muslims? (2002), and When Progressives Treat with Reactionaries: The British State's flirtation with radical Islamism (2006), a report for the Policy Exchange, Bright examined issues of contemporary Muslim community in the United Kingdom. Tom Brook (born 16 June 1953); broadcaster and journalist working primarily for BBC News, BBC World News, BBC News Channel and Talking Movies. Brook's parents were Caspar Brook, the first director of the Consumers' Association in Britain, and Dinah, journalist for The Observer. Tina Brown, Christina Hambley Brown, Lady Evans (born 21 November 1953), is an English journalist, magazine editor, columnist, talk-show host, and author of The Diana Chronicles (2007) a biography of Diana, Princess of Wales, The Vanity Fair Diaries (2017) and The Palace Papers (2022).
Sources: en.wikipedia.org
Design qualification (DQ)- Demonstrates that the proposed design (or the existing design for an off-the-shelf item) will satisfy all the requirements that are defined and detailed in the User Requirements Specification (URS). Satisfactory execution of the DQ is a mandatory requirement before construction (or procurement) of the new design can be authorised. Installation qualification (IQ) – Demonstrates that the process or equipment meets all specifications, is installed correctly, and all required components and documentation needed for continued operation are installed and in place. Operational qualification (OQ) – Demonstrates that all facets of the process or equipment are operating correctly. Performance qualification (PQ) – Demonstrates that the process or equipment performs as intended in a consistent manner over time. Component qualification (CQ) – is a relatively new term developed in 2005. This term refers to the manufacturing of auxiliary components to ensure that they are manufactured to the correct design criteria. This could include packaging components such as folding cartons, shipping cases, labels or even phase change material. All of these components must have some type of random inspection to ensure that the third party manufacturer's process is consistently producing components that are used in the world of GMP at drug or biologic manufacturer. There are instances when it is more expedient and efficient to transfer some tests or inspections from the IQ to the OQ, or from the OQ to the PQ.
Freeman's performance was praised by film critics, including Roger Ebert who wrote: "Freeman has the flashier role, as a smart, very tough man who can be charming or intimidating-whatever's needed ... Freeman creates such an unforgettable villain." Freeman's performance earned him an Academy Award nomination for Best Supporting Actor. He later said that he considered Street Smart to be his breakthrough role. In his next film, he played Craig in the drama Clean and Sober with co-stars Michael Keaton and Kathy Baker. Although the film was not a box-office hit, it gained fair reviews; Roger Ebert gave the film 31⁄2 out of 4 stars and called the performances "superb". Freeman also received Obie Awards for his roles as a preacher in the musical The Gospel at Colonus, and as Hoke Colburn in the play Driving Miss Daisy, respectively.
In 2008, the EPA approved natural broad-spectrum elicitor status for an ultralow molecular active ingredient of 0.25% chitosan. A natural chitosan elicitor solution for agriculture and horticultural uses was granted an amended label for foliar and irrigation applications by the EPA in 2009. Given its low potential for toxicity and abundance in the natural environment, chitosan does not harm people, pets, wildlife, or the environment when used according to label directions. Chitosan blends do not work against bark beetles when put on a tree's leaves or in its soil.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.